Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06839131

A Clinical Study of SPH9788 Tablets in Healthy Chinese Subjects.

A Randomized, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of SPH9788 Tablet in Chinese Healthy Subjects.

Status
Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
94 (estimated)
Sponsor
Shanghai Pharmaceuticals Holding Co., Ltd · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The purpose of the study is to evaluate the safety of SPH9788 tablets in healthy subjects.

Conditions

Interventions

TypeNameDescription
DRUGSPH9788SPH9788 tablets administered orally
DRUGPlaceboMatching placebo administered orally

Timeline

Start date
2025-03-02
Primary completion
2025-12-31
Completion
2025-12-31
First posted
2025-02-21
Last updated
2025-03-26

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06839131. Inclusion in this directory is not an endorsement.